

KILITCH DRUGS (INDIA) LIMITED

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2014


Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN. L24239MH1992PLC066718

Rs. in Lacs

PART I Sr. No.	Particulars	Three Months Ended			Year ended
		6/30/2014	3/31/2014	6/30/2013	3/31/2014
		Unaudited	Audited	Unaudited	Audited
1	Income from operations				
	(a) Net Sales/Income from operations(net of Excise)	556.04	633.57	368.66	1421.49
	(b) Other operating income	14.66	(20.31)	0.00	68.31
	Total Income from Operations (Net)	570.70	613.26	368.66	1489.80
2	Expenses				
	(a) Cost of materials consumed	152.92	406.34	237.67	774.77
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	115.33	25.76	(44.04)	(145.96)
	(c) Employee Benefit Expenses	78.94	90.08	60.80	285.76
	(d) Depreciation and Amortisation Expenses	52.81	44.94	33.08	143.97
	(e) Export Product Registration Charges	47.92	111.87	0.00	183.18
	(f) Other Expenses	161.63	363.01	109.52	770.89
	Total Expenses	609.54	1042.00	397.03	2012.62
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(38.84)	(428.74)	(28.37)	(522.82)
4	Other Income	66.19	174.86	210.52	629.12
5	Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	27.34	(253.88)	182.15	106.30
6	Finance Costs	0.00	0.00	6.18	0.00
7	Profit / (Loss) from ordinary activities before exceptional items (6-6)	27.34	(253.88)	175.97	106.30
8	Exceptional Items	0.00	0.00	0.00	0.00
9	Profit / (Loss) from ordinary activities before tax (7+8)	27.34	(253.88)	175.97	106.30
10	Tax Expenses				
	Current Tax	0.00	(60.00)	0.00	0.00
	Deferred Tax	(22.50)	(6.34)	0.00	(10.35)
	Tax Adjustments of Earlier years	0.00	(1.00)		(1.00)
11	Net Profit / (Loss) from ordinary activities after tax (9-10)	49.84	(184.54)	175.97	117.65
12	Extra Ordinary Items (net of tax expenses)	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11+12)	49.84	(184.54)	175.97	117.65
14	Paid-Up equity share capital (Face Value Rs. 10 per share)	1323.18	1323.18	1323.18	1323.18
15	Reserve excluding Revaluation Reserve [As per the latest Audited Balance Sheet]				10699.65
16.I	Earnings per share (before extra ordinary items) (F.V. of Rs.10/-each) (not annualised):				
	(a) Basic	0.38	(1.39)	1.33	0.89
	(b) Diluted	0.38	(1.39)	1.31	0.89
16.II	Earnings per share (after extra ordinary items) (F.V. of Rs.10/-each) (not annualised):				
	(a) Basic	0.38	(1.39)	1.33	0.89
	(b) Diluted	0.38	(1.39)	1.31	0.89




PART #	Particulars	Three Months Ended			Year ended
		6/30/2014	3/31/2014	6/30/2013	3/31/2014
A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding				
	a) Number of shares	4697655	4697655	4706393	4697655
	b) Percentage of shareholding	35.50	35.50	35.57	35.50
2	Promoters and Promoter Group Shareholding				
	a) Pledge / Encumbered				
	Number of shares				
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)				
	Percentage of shares (as a % of the total share capital of the company)				
	b) Non-encumbered				
	Number of shares	8534173	8534173	8525435	8534173
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100	100	100	100
	Percentage of shares (as a % of the total share capital of the company)	64.50	64.50	64.43	64.50

B INVESTOR COMPLAINTS	
Pending at the beginning of the Quarter	NIL
Received during the quarter	7
Disposed off during the quarter	7
Remaining unresolved at the end of the quarter	NIL

Notes:

- The above results as reviewed by the audit committee have been taken on record by the Board of Directors at their meeting held on 14th August, 2014.
- During the quarter, the Company has operated only in one reportable segment i.e. Pharmaceuticals.
- The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods. The Figures of the last quarter of previous financial year are the balancing figures between audited figures in respect of the full previous financial year and published year to date figures upto the third quarter of the previous financial year.
- Consequent to the enactment of the Companies Act, 2013 (the Act) and its applicability for the accounting year with effect from 1st April, 2014, the company has computed depreciation with reference to the estimated economic lives of fixed assets prescribed by the Schedule II to the Act or actual useful life. For the assets, whose life has been completed as above, the written down value not of residual value as at April 1, 2014 has been adjusted to retained earnings and in other cases the carrying value as at 1st April, 2014 has been depreciated over the remaining useful life of the assets and accordingly recognised in the above financial results.

Place: Mumbai
Date: 14th August, 2014



A.M.GHELANI & COMPANY

CHARTERED ACCOUNTANTS

AJIT M. GHELANI

B.Com.(Hons), F.C.A., GRAD. C.W.A.

CHINTAN A. GHELANI

B.Com.(Hons), F.C.A., C.S.

To,


The Board of Directors


KILITCH DRUGS (INDIA) LIMITED

**LIMITED REVIEW REPORT OF THE UNAUDITED STANDALONE RESULTS OF
KILITCH DRUGS (INDIA) LIMITED FOR THE QUARTER ENDED 30.06.2014**

1. We have reviewed the accompanying statement of unaudited standalone financial results of M/s. **Kilitch Drugs (India) Limited** for the quarter ended 30th June, 2014, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 with the General Circular 15/2013 dated 13/09/2013 of the Ministry of Corporate Affairs in respect of section 133 of the Companies Act, 2013 and other recognized accounting practices and policies generally accepted in India has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. M. Ghelani & Company
Chartered Accountants
(Firm Registration No. 103173W)


Chintan A. Ghelani
Partner
Membership No. 104391



Place: Mumbai
Date: 14-08-2014

Enclosed : Unaudited financial results for the quarter ended 30th June, 2014 of M/s. **Kilitch Drugs (India) Limited**.